Key Takeaways
- Margins nearly doubled QoQ despite a volume dip: EBITDA margin recovered sharply even as sales quantity fell ~8-9% in the seasonally lean paint quarter, driven by lower material and power costs.
- Isosteric acid is the margin reset story: The new high-value product has cleared technical hurdles, drawn surprise and interest from US and European buyers, and is entering the final approval stage before commercial shipments.
- China dumping distorted one quarter, then stopped: Chinese players dumped dimer acid briefly, creating price pressure that bled into July; management expects Q3 to be the first clean quarter, provided dumping does not recur.
- Raw material volatility has eased: Vegetable oil price swings of ~10% intra-month hurt purchasing and availability earlier, but the last 2-3 months have seen significant stabilization.
- What to watch next quarter: Whether isosteric acid wins final customer approvals and begins commercial shipments, the pace of the margin climb toward the 12-13% Q3 target, and any sign of renewed Chinese dumping.
Isosteric Acid: The New Growth Vector
- Product profile: A high-value specialty acid previously made only by two US and two European players; Fairchem is the first Indian entrant into a market with a demand-supply mismatch.
- Market reception: US and European specialty companies were "pleasantly surprised" that an Indian company is venturing into this space, and substantial orders have already been received.
- Approval status: Now in the third and final stage (plant sample approval); stability tests of 90-120 days are underway with multinational customers, with fortnightly feedback showing nothing negative so far.
- Ramp-up timeline: Management is optimistic about commencing commercial shipments in the January-March quarter, with volumes picking up further from April-June onwards; by FY25, isosteric acid should be "really picking up."
- Margin contribution: As a value-added product, isosteric acid is central to the path back to 15-16% EBITDA margins; management declined to disclose product-level margins.
Nahoosh Jariwala: "USA and European specialty companies were pleasantly surprised by the fact that an Indian company is venturing in the global market of isosteric acid, which hitherto has been the domain of European and U.S. companies only."
Margin Recovery: Drivers and Trajectory
- Q2 margin jump: EBITDA percentage nearly doubled QoQ, helped by a lower percentage of material consumption relative to sales and a reduction in power and fuel cost.
- The drag is receding: Trial run costs and plant costs for new product development were concentrated in Q1 and Q2, especially Q1; by Q2, processes were settled.
- Raw material stabilization: Vegetable oil price variation, which had been ~10% between the start and end of a month, has reduced significantly over the last 2-3 months, improving purchasing conditions.
- Value-added shift in existing products: The company is now selling stearic acid (a value-added product) instead of palmitic acid, selling 100% of what it makes; this will not move the top line much but will improve the bottom line.
- Sequential path: Management expects Q3 margins to be "100% better" than Q2, reaching about 12-13% EBITDA, and then subsequently climbing to 15% if conditions remain stable.
Nahoosh Jariwala: "to be frank, our internal goal always has been to remain in 14% to 16% EBITDA range. We strive to reach there only, but many times the external factors are such that they are beyond our control, and we cannot do anything about it."
Demand and Volume Dynamics
- Seasonal volume dip: The ~8-9% decline in sale quantity was driven by July-September being the lean period for the paint industry, when painting activity normally halts.
- Customer base intact and expanding: The company has retained all its customers and added a significant new customer in linoleic acid; in dimer acid, the entire customer set is different, and Fairchem supplies linoleic acid to all four big paint players.
- New paint industry approvals secured: Products are already approved by newer paint industry entrants including Grasim and JSW, broadening the addressable base.
- Volume growth certainty: Management is certain of achieving growth in quantity processed and sold; the top line, however, will depend substantially on refined oil prices, which are not in the company's control.
- Capacity utilization: Expected to increase going forward as new products ramp up and demand normalizes.
China Dumping: A One-Quarter Distortion
- What happened: Chinese players dumped dimer acid for one quarter, creating price pressure; they stopped because they could not sustain the business at a loss.
- Residual impact: Some effect of the April-June dumping carried into July, so Q3 (October-December) will be the first quarter entirely free of that drag, provided no further dumping occurs.
- Recurrence risk: Management does not expect continuous dumping and notes it happened for the first time, but cannot guarantee it will never happen again.
- Competitive insulation: Fairchem's ability to purchase raw material at higher prices, because it makes value-added products, gives it an edge over small players who cannot do the same.
Raw Material and Competitive Position
- Raw material availability: Management clarified the company has never shut a plant due to lack of raw material; it has enough storage capacity and the ability to pay up for feedstock because of its value-added product mix, unlike smaller competitors.
- Palm oil linkage: If palm oil prices are low and more palm oil processing occurs, less soft oil gets processed, reducing the availability of waste from soft oils, which theoretically impacts Fairchem negatively.
- Finished product pricing: Prices are stable, and management is happy with current pricing; spreads in Q3 are expected to be better than in Q2.
- Competitive moat in India: There is no other Indian producer of isosteric acid, and the global market has only four incumbent players (two in the US, two in Europe).
Nahoosh Jariwala: "There is nobody in India."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Isosteric acid commercial shipments | Begin supplies immediately upon approval; stability tests of 90-120 days underway | January-March quarter (optimistic) |
| Q3 EBITDA margin | Reach about 12-13% | Q3 FY24 (October-December) |
| Subsequent margin target | Reach 15% EBITDA margin | After Q3, if conditions remain stable |
| Full margin recovery | Return to 15-16% EBITDA range, driven by isosteric acid ramp and higher utilization | April-June quarter onwards |
| EBITDA aspiration | Achieve roughly ₹150 crores of EBITDA; all investments done, product development over | Two years down the line (aspiration, not firm guidance) |
| Volume growth | Certain to achieve growth in quantity processed and sold | Ongoing |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue from operations | ₹148 cr |
| EBITDA | ₹18 cr |
| EBITDA margin | 12.16% |
| Net profit | ₹10 cr |
| PAT margin | 6.77% |
| H1 FY24 revenue from operations | ₹313 cr |
| H1 FY24 EBITDA | ₹29 cr, EBITDA margin 9.11% |
| H1 FY24 net profit | ₹16 cr, PAT margin 5.24% |
| Finished goods sales volume change | ~8% decline QoQ |
| Finished goods sales value change | ~5% decline QoQ |
| Quantity processed change | ~9% increase QoQ |
| Capacity utilization | ~65% |
| Revenue mix: Paint, printing & adhesive | ₹117.30 cr |
| Revenue mix: Nutraceutical | ₹8.4 cr |
| Revenue mix: Soap, fuel, etc. | ₹22.9 cr |
| Isosteric acid peak capacity revenue potential | ₹100–125 cr per annum |
| Isosteric acid stability test approval timeline | 90 to 120 days |